Will the approval of one or more AD drug unleash the use of amyloid PET imaging?

Based on World Health Organization, Alzheimer's and dementia's diseases are the 7th leading cause of mortality worldwide1. Recently, a new Alzheimer's disease imaging drug has been approved and reimbursed in the US and in Japan. Amyloid PET imaging plays crucial role in the selection of patients that will likely benefit from these new treatments. In this webinar, 2 renowned experts reply to the main question: Will the Approval of Novel Alzheimer's Disease Drugs Unleash the Use of Amyloid PET Imaging?

This webinar is already ready over. Missed the live webinar or want to rewatch it?

Speakers

Prof Dr Henryk Barthel

Assistant Medical Director Brain PET and PET/MRI Department of Nuclear Medicine

Leipzig University Medical Center, Germany
Dr Fujibayashi

Chief Technology Officer

CMI, Japan
Topics
- The European perspective on the challenges and opportunities related to the anticipated approval of Alzheimer's drugs in Europe.
- Navigate through the regulatory landscape of amyloid PET imaging in Japan by giving you the current status and future directions.